EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program

Beverly G Tchang iD, Andreea Ciudin Mihai, Adam Stefanski, Luis-Emilio García-Pérez, Donna Mojdami, Irina Jouravskaya, Sirel Gurbuz, Rebecca Taylor, Chrisanthi A Karanikas, Julia P Dunn iD

Obesity · 2025-05 · 33 (5) · 851-860

DOI: 10.1002/oby.24254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 12.03.2025. Verfasst von Beverly G Tchang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, Ne…. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Weight Loss. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage.

Methods

Women participants from SURMOUNT‐1, ‐3, and ‐4 randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo were retrospectively categorized as being in the pre‐, peri‐, or post‐menopause stages. Body weight and waist circumference changes, the proportion of participants achieving body weight‐reduction thresholds, and waist to height ratio (WHtR) category shift among those with baseline BMI < 35 kg/m 2 were assessed at end of study treatment.

Results

In SURMOUNT‐1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001). Greater waist circumference reductions were also observed with tirzepatide across the subgroups (22 vs. 4 cm, 20 vs. 5 cm, and 20 vs. 4 cm, respectively; p < 0.001). Across the reproductive stage subgroups, 97% to 98% of participants achieved body weight reductions that were ≥5% with tirzepatide versus 29% to 33% with placebo. Furthermore, 30% to 52% of women among the reproductive stage subgroups who had baseline BMI < 35 kg/m 2 reached WHtR ≤ 0.49 (low central adiposity) with tirzepatide. Similar results were observed in SURMOUNT‐3 and ‐4.

Conclusions

In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityWeight LossAdultFemaleHumansMiddle AgedAdiposityBody Mass IndexBody WeightDouble-Blind MethodMenopausePostmenopausePremenopauseRetrospective StudiesTirzepatideWaist CircumferenceClinical Trials, Phase III as TopicRandomized Controlled Trials as TopicSecondary Data Analysis

Substanzen

Anti-Obesity AgentsTirzepatide

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, New York, USA.
  • Endocrinology and Nutrition Department, Vall d'Hebron Institut de Recerca (VHIR; Vall d'Hebron Research Institute), Hospital Universitari Vall d'Hebron (Vall d'Hebron University Hospital), Vall d'Hebron Barcelona Campus…
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Beverly G Tchang, Julia P Dunn

Förderung

  • Eli Lilly and Company

Zitieren

APA

Tchang, B. G., Mihai, A. C., Stefanski, A., García-Pérez, L. E., Mojdami, D., Jouravskaya, I., Gurbuz, S., Taylor, R., Karanikas, C. A., & Dunn, J. P. (2025). Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity, 33(5), 851-860. https://doi.org/10.1002/oby.24254

Vancouver

Tchang BG, Mihai AC, Stefanski A, García-Pérez LE, Mojdami D, Jouravskaya I, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity. 2025;33(5):851-860. doi:10.1002/oby.24254

BibTeX
@article{Tchang2025,
  author = {Tchang, Beverly G and Mihai, Andreea Ciudin and Stefanski, Adam and García-Pérez, Luis-Emilio and Mojdami, Donna and Jouravskaya, Irina and Gurbuz, Sirel and Taylor, Rebecca and Karanikas, Chrisanthi A and Dunn, Julia P},
  title = {Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {5},
  pages = {851--860},
  doi = {10.1002/oby.24254}
}
Kostenlos starten →